• news

    New and Innovative Approaches to Laboratory Diagnosis of Zika, Dengue and other Arboviruses

April 28, 2017 - Les Pensières Center for Global Health, Veyrier du Lac, France

The purpose of this workshop is to review novel technologies, to identify which characteristics should be prioritized, how to meet regulatory requirements, and how to move from innovation to market.

Despite advances in diagnostics for flaviviral infections, there is a critical need for more sensitive, specific, easy to use and affordable tests for point of care (POC) diagnosis, multiplex virologic and serologic assays to differentiate co-circulating viruses of public health significance, eg, dengue, Zika, yellow fever and chikungunya, and methods for viral quantification and genomic characterization. New diagnostic methods continue to be innovated, such as microfluidics, paper-based diagnostics, chip-based systems, micro- and nanofabrication technologies, deep sequencing, among others.

Towards the development of new technologies

The Partnership for Dengue Control (PDC) wishes to cast a wider net to facilitate and expedite the development of the most promising technologies that are urgently needed not only for pressing research questions but also to be rolled out in affected countries. The Flavivirus field can learn from cutting-edge technologies that have been developed for diseases such as HIV, malaria and Tuberculosis. Hence the workshop is organized around three questions:

  • What is the current status of Zika and dengue diagnostics?
  • What new technologies might be available in the near, intermediate and long-term future?
  • What is needed to make these technologies available?


  • May Chu, Colorado School of Public Health, Clinical Professor
  • Duane Gubler, Duke-NUS Medical School, Emeritus Professor
  • Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
  • Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research

Scientific Committee

  • Arlene Chua, World Health Organization, Technical Consultant
  • Duane Gubler, Duke-NUS Medical School, Emeritus Professor
  • Eva Harris, University of California, Berkeley, Professor
  • Aravinda de Silva, University of North Carolina School of Medicine, Professor
  • Bernadette Murgue, WHO, R&D Blueprint manager
  • Maurine Murtagh, The Murtagh Group, LLC Principal
  • Rosanna Peeling, London School of Hygiene and Tropical Medicine, Professor and Chair, Diagnostics Research
  • Annelies Wilder-Smith, Foundation PDC, Director of the Partnership for Dengue Control and Professor of Infectious Diseases Research

Organized by the Partnership for Dengue Control (PDC) and the Mérieux Foundation (France), with the support of the Bill & Melinda Gates Foundation, bioMérieux, Takeda and Sanofi Pasteur.


Download Program

Tuesday, May 2 – Day 1

Where are we now?

1.30pm – 3pm Session 1

Chairs: Annelies Wilder-Smith, Duane Gubler

  • Setting the objectives of the meeting – Annelies Wilder-Smith, PDC
  • What are the necessary characteristics of diagnostic assays depending on the intended use: case management, surveillance, serosurveys, research studies, intervention trials – Duane Gubler, GDAC
  • Review of Zika standard assays (CDC MAC, IgG and PRNT) – Aravinda de Silva for Amy Lambert, CDC
  • Landscape analysis of the current status of Flavivirus diagnostics (dengue and Zika) – Maurine Murtagh, The Murtagh Group
Coffee break
3.30pm – 5pm Session 2

Chairs: Francis Moussy, Amy Lambert

  • Learning from successful novel technologies that made it to the market – Mark Miller, BioMerieux
  • Demand forecasting and market considerations – Nagwa Hasanin, UNICEF
  • Learning from past emergency authorizations – Elliot Cowan, Partners in Diagnostics
Networking session
6.00pm – 7.00pm Evening
Chair: May ChuTalk: Zika and dengue diagnostics from a strategic investor’s perspective – Julie Schäfer, BARDA
Cocktail Dinner

Wednesday, May 3 – Day 2

Where do we go? Technological innovations in Flavivirus diagnostics

8.30am – 12.30pm Session 3: Detecting acute infection

Chairs: Maurine Murtagh, Arlene Chua

  • Imminent technological innovations
  • Cutting edge innovations for the intermediate and long-term future
  • Discussion
8.30am – 10.00am
  • Near-care molecular testing for Dengue, Zika and related pathogens – Jesse Waggoner, Emory University
  • Development of molecular tests for management of febrile illnesses and diagnosis of viral haemorrhagic fever – Kevin Arien, ITM
  • Tetracore T-COR8 diagnostic system for the detection of Dengue and other arboviruses using real-time-rtPCR at the point-of-care – Bill Nelson, Tetracore
  • Triplex PCR ZIKV/DENV/CHIKV assay and simple to operate real-time portable device – Craig Mosman, Kirkland Biosciences
Coffee break
10.30am – 12.30pm
  • Molecular test to detect dengue, Zika & Chikungunya and run on the QuRapID LV platform – Emily Adams, LSTM & David Edge, BioGene
  • NS1 antigen capture assays for the specific detection of different dengue virus serotypes and other arboviruses – Katharina Roeltgen, Swiss TPH
  • Application of a parsimonious targeted-enrichment methodology for full-genome sequencing of viral genomes directly from patient samples – October Sessions, Duke-NUS
  • Multiplex Diagnosis kit for Zika, Dengue, Chikungunya and Japanese Encephalitis Viruses using Printed Array Strip based on Single-stranded Tag Hybridization method – Takahiro Haruyama, AVSS
  • Multiplex magneto-optical detection technique – John Lewandowski, MIT
  • Discussion
2pm – 5.45pm Session 4: Detecting past infections

Chairs: Eva Harris, Aravinda de Silva

2pm – 3.40pm Dx antigen discovery and imminent technological innovations

  • New discoveries about the molecular specificity of the human antibody response to dengue and Zika viruses – Aravinda de Silva, UNC
  • NS1 blockade-of-binding ELISA distinguishes between dengue and Zika virus antibodies – David Corti – Humabs BioMed SA
  • In-country development and evaluation of new molecular and serological methods for Zika diagnosis and surveillance and their applications – Eva Harris, Berkeley University
  • Structure based design of novel Zika virus antigens for serodiagnosis – Prem Lakshmanane, UNC-CH, North Carolina
Coffee Break
4.00pm – 5.00pm Cutting Edge Innovations For The Intermediate And Long-Term Future

  • VIDAS Zika and Dengue: Preliminary results on an automated immunoAssay platform – Nathalie Renard, Biomerieux
  • VIRO-TRACK – A rapid, quantitative, and accurate dengue/zika diagnostics platform for point of care use in endemic regions – Filippo Giacomo Bosco, BluSense Diagnostics ApS
  • A nanoscale plasmonic-gold platform for specific diagnosis of Zika and differentiation from other Flavivirus infections – Benjamin A. Pinsky, Stanford, CA
5.00pm – 5.45pm Discussion

Thursday, May 4 – Day 3

How do we make it happen? From idea to market

8.30am – 10am Session 5: Preparing for the inevitable: open technology platforms for rapid outbreak response

Chairs: Bill Rodriguez, Bernadette Murgue

Preparing for the inevitable: open platform technologies for rapid outbreak response

  • WHO call for open technology platforms to accelerate test development – Bernadette Murgue, WHO Blueprint
  • Diagnostics preparedness platform – Thomas Ullrich, Alere
  • Learning from influenza POCT – Julie Schäfer, BARDA
  • Genetic analysis tool kit for rapid outbreak response – Michael Baffi, Thermo Fisher
Coffee break
10.30am – 12.30pm Session 6: Critical steps to ensure quality products

Chairs: Rosanna Peeling, Piero Olliaro

  • Critical steps to ensure quality products – Bill Rodriguez
  • Lessons learnt on bringing diagnostics to the market in low and middle income countries – Cassandra Kelly, FIND
  • Two new WHO IVD initiatives: SAGE-IVD and EDL – Francis Moussy, WHO Blueprint
  • Regional regulatory harmonization working parties – Rosanna Peeling, LSHTM
  • Streamlining from bench-to-bedside – Piero Olliaro, WHO TDR
  • Panel Discussion
1.30pm – 3:30pm Session 7: Identifying PDC’s roles to support innovative diagnostics

Chairs: May Chu, Julie Schäfer

  • Panel 1: Networks and alliances – Dhamari Naidoo, WHO; Maria Guzman, RELDA Cuba; Amadou Sall, Institute Pasteur Senegal; Francois Xavier Babin, Merieux (Networks of Laboratories);
    Annelies Wilder-Smith and In-Kyu Yoon, GDAC
  • Panel 2: Accelerating from ideas to market – Jennifer Fluder, USAID; Rosanna Peeling, LSHTM; Thomas Ullrich, Alere
  • Panel 3: Views from stakeholders and partners – Sumi Paranjape, Vulcan; Nagwa Hasanin, UNICEF; Julie Schäfer, BARDA
  • Concluding Discussion: research agenda and roadmap for the next 12 months
3.30pm – 4pm Summary and Recommendations – May Chu, Rosanna Peeling and Annelies Wilder-Smith
Coffee Break